Paediatric Clinical Trials

31^ST March – 1^ST April 2014

The Kensington Close Hotel, London UK 

Sponsored by PPD

Building on the success of our previous events, SMi is proud to present the 8th instalment in the popular conference series; Paediatric Clinical Trials , taking place on 31st March and 1st April 2014, London UK.

This event will bring together key opinion leaders to provide attendees with an in depth look into current advances in paediatric clinical trials and drug development with a complete view of the paediatric market.

Presentations will focus on regulatory requirements, challenges in clinical trials design, formulation development, extrapolation form the adult population plus much more.

Why Attend this Event in 2014:

• Discuss the global paediatric legislations and an impact assessment of the EU legislation

• Learn about PIP submissions

• Discover how the FDA changes the regulatory landscape for paediatric drug development in the US

• Explore how clinical trials are organised in Hungary

• Analyse vaccines trials vs. antibiotic trials

• Evaluate the experience of a paediatrics ethics committee

• Examine extrapolation in paediatric drug development

• Consider formulation development and paediatric psychopharmacology

Key Speakers:

• Bruno Reigner, Senior Clinical Pharmacologist, Roche Pharmaceuticals

• David McIntosh, Global Scientific Affairs Senior Expert, Novartis Vaccines

• Philippe Auby, Director, International Clinical Research, Paediatric Neuro-Psychiatry, Lundbeck

• Christina Bucci-Rechtweg, Head, Maternal & Paediatric Regulatory Policy, Novartis

• Klaus Rose, CEO, Klausrose Consulting

• Elin Haf Davies, Director & Founder, Empowering Children | Enabling Research

• Daniel Bar-Shalom, Associate Professor, University of Copenhagen

• Daniel De Wolf, Director - Department of Paediatric Cardiology, Ghent University Hospital

• Karl-Heinz Huemer, Scientific Office, Austrian Agency for Health and Food Safety

• Otto Skoran, CEO, Svabhegy Paediatric Hospital

• Mark Sorrentino, Executive Medical Director, PPD Consulting

Previous instalments received positive feedback from the industry including, "Good presentations and important topics" – Abbott, "I very much enjoyed this conference, thanks to the organisers" – UCB and "Very good meeting" - Boehringer Ingelheim

Asthma and COPD 2014

April 2-3 2014

Marriott Regents Park Hotel, London UK

Hear the latest regulatory requirements to develop inhaled products and enhance clinical design on April 2-3 2014 in Marriott Regents Park Hotel, London UK

SMi proudly present the 10th annual Asthma and COPD conference taking place in Central London on Wednesday 2nd and Thursday 3rd April, 2014.

Due to the world's increasingly aging population and rising pollution levels, the global market for asthma and chronic obstructive pulmonary disease (COPD) drugs is set to reach $47bn in 2017.

There is a growing demand for the next generation of inhaled combination products and novel therapeutics. This conference will enable delegates to gain valuable insight into the latest ground-breaking advances in the respiratory drug market. It will focus on the challenges and strategies to enhance patient outcomes, providing extensive knowledge from the key leading industry and academic experts.

The agenda will showcase the treatment for exacerbations, clinical trial design and strategies for method enhancement, biomarkers and the utilisation of devices for Asthma and COPD. Key focus will be put on the anti-inflammatory developments in addition to the efficacy and toxicological issues relating to combination products.

Insight will be given on the current regulatory requirements and enable delegates to stay up to date with the guidelines.

BUSINESS BENEFITS FOR 2014:

• NEW FOR 2014 - Four round table discussions to enhance networking capabilities between delegates and sponsors

• Hear the latest regulatory advice from the MHRA on new inhaled drugs

• Evaluate strategies to enhance clinical trial design with key talks from Teva and AstraZeneca

• Listen to case studies from University College London and Theravance Inc. on the late stage developments of combination therapies

• Gain insight on U-BIOPRED from committee members, Novartis, the British Lung Foundation and the National Heart & Lung Institute

CHAIRMEN FOR 2014:

Noel Snell, Director of Research, British Lung Foundation

Jorgen Vestbo, Professor of Respiratory Medicine, University of Southern Denmark

KEY SPEAKERS INCLUDE:

Christine Ward, Principal Scientist, Translational Medicine-RIA, MedImmune

Paul Whittaker, Director/Unit Head for Pre-Clinical Biomarkers Respiratory Disease Area, Novartis

Dr Nithyanandan Nagercoil, Senior Medical Assessor, MHRA

Fan Chung, Professor of Respiratory Medicine and Head of Experimental Studies Medicine, National Heart & Lung Institute

Matthew Catley, Team Leader RIA, AstraZeneca

The 10^th annual event is now well known and established within the industry.

Comments from previous instalments include: “Excellent, both days” – Prosonix, “Good Networking opportunities” – Novartis

Asthma and COPD 2014 will focus on the cutting edge concepts driving the developments of asthma and COPD forward. This truly is a must attend for respiratory professional.

Asthma and COPD 2014

April 2-3 2014

Marriott Regents Park Hotel, London UK

Hear the latest regulatory requirements to develop inhaled products and enhance clinical design on April 2-3 2014 in Marriott Regents Park Hotel, London UK

SMi proudly present the 10th annual Asthma and COPD conference taking place in Central London on Wednesday 2nd and Thursday 3rd April, 2014.

Due to the world's increasingly aging population and rising pollution levels, the global market for asthma and chronic obstructive pulmonary disease (COPD) drugs is set to reach $47bn in 2017.

There is a growing demand for the next generation of inhaled combination products and novel therapeutics. This conference will enable delegates to gain valuable insight into the latest ground-breaking advances in the respiratory drug market. It will focus on the challenges and strategies to enhance patient outcomes, providing extensive knowledge from the key leading industry and academic experts.

The agenda will showcase the treatment for exacerbations, clinical trial design and strategies for method enhancement, biomarkers and the utilisation of devices for Asthma and COPD. Key focus will be put on the anti-inflammatory developments in addition to the efficacy and toxicological issues relating to combination products.

Insight will be given on the current regulatory requirements and enable delegates to stay up to date with the guidelines.

BUSINESS BENEFITS FOR 2014:

• NEW FOR 2014 - Four round table discussions to enhance networking capabilities between delegates and sponsors

• Hear the latest regulatory advice from the MHRA on new inhaled drugs

• Evaluate strategies to enhance clinical trial design with key talks from Teva and AstraZeneca

• Listen to case studies from University College London and Theravance Inc. on the late stage developments of combination therapies

• Gain insight on U-BIOPRED from committee members, Novartis, the British Lung Foundation and the National Heart & Lung Institute

CHAIRMEN FOR 2014:

Noel Snell, Director of Research, British Lung Foundation

Jorgen Vestbo, Professor of Respiratory Medicine, University of Southern Denmark

KEY SPEAKERS INCLUDE:

Christine Ward, Principal Scientist, Translational Medicine-RIA, MedImmune

Paul Whittaker, Director/Unit Head for Pre-Clinical Biomarkers Respiratory Disease Area, Novartis

Dr Nithyanandan Nagercoil, Senior Medical Assessor, MHRA

Fan Chung, Professor of Respiratory Medicine and Head of Experimental Studies Medicine, National Heart & Lung Institute

Matthew Catley, Team Leader RIA, AstraZeneca

The 10^th annual event is now well known and established within the industry.

Comments from previous instalments include: “Excellent, both days” – Prosonix, “Good Networking opportunities” – Novartis

Asthma and COPD 2014 will focus on the cutting edge concepts driving the developments of asthma and COPD forward. This truly is a must attend for respiratory professional.